New hope to shield patients from Chemo's harshest side effects
NCT ID NCT07490236
Summary
This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage during chemotherapy for solid tumors. The goal is to reduce severe drops in blood cell counts, which can be dangerous and delay cancer treatment. Researchers will study 100 patients to see if the drug helps them complete their chemotherapy on schedule with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRILACICLIB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050300, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.